A股異動 | 通富微電升9% 第三代半導體碳化硅產品通過客户考核並進入量產
格隆匯3月3日丨通富微電(002156.SZ)升8.9%,報23.99元,總市值363億元,創2022年8月12日新高。通富微電在互動平台表示,公司開啟“立足7nm、進階5nm”的戰略,深入開展5nm新品研發,全力支持客户5nm產品導入,現已完成研發逐步量產,助力大客户高端進階,有信心能夠滿足大客户今後在芯片製程進階後的封測需求。公司具備相關先進封測技術後,將努力盡快實現大規模量產。公司表示,公司2022年已為國際知名汽車電子客户開發的第三代半導體碳化硅產品,具備無鉛化、耐高壓、高功率等優勢,應用於客户新能源車載逆變器等領域,在國內首家通過客户考核並進入量產。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.